Search

To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center.

… Saturday, January 1, 2011 Summary To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center. To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center. The goal of the new

Thanks to pioneering work done at MSK, a powerful new form of radiation therapy is changing the treatment of advanced cancers.

… Thursday, September 11, 2025 A high-intensity radiation beam that penetrates the body to burn away tumors has been a standard weapon against cancer for more than a century. Over the years, radiation therapy has improved dramatically, but its effectiveness against cancers in multiple places can be limited

The July 22 MSK Science Spotlight features Luis Diaz, MD, Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.”

… Wednesday, July 22, 2020 The July 22 MSK Science Spotlight features Luis Diaz, MD , Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.” An accomplished physician, pioneering researcher, and leader in the field

You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also approved the Guardant360 CDx assay, a companion liquid biopsy diagnostic device for identifying patients for treatment.

… Wednesday, March 8, 2023 You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also

Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells.

… Monday, October 8, 2012 Summary Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells. For the first time, a team of Memorial Sloan Kettering investigators has synthesized erythropoietin (also known as EPO), the hormone

Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer discovery at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, in San Diego, California.

… Tuesday, April 14, 2026 Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer discovery at the American Association for Cancer Research (AACR) Annual Meeting 2026

Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the best cancer center in the Northeast, the number two cancer hospital in the nation, and the number one hospital for urology care by U.S. News & World Report in its annual Best Hospitals list. MSK has held its position as a top-two cancer hospital in the U.S. and the best cancer center in the Northeast since these rankings were established 35 years ago.

… Tuesday, July 16, 2024 Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the best cancer center in the Northeast, the number two cancer hospital in the nation, and the number one hospital for urology care by U.S. News & World Report in its annual Best Hospitals list. MSK has held its

MSK researchers have led much of the research looking at how people with blood cancers respond to COVID-19 infections and vaccines.

… Tuesday, December 21, 2021 Doctors and scientists at Memorial Sloan Kettering Cancer Center have played a leading role in understanding how COVID-19 affects people with cancer. MSK investigators have published a number of pioneering studies on the topic, which have contributed to the care of patients

… Wednesday, August 3, 2022 First, the good news: There’s no evidence that tattoos cause skin cancer , says Memorial Sloan Kettering Cancer Center (MSK) dermatologist Jennifer DeFazio , who cares for people at the MSK Skin Cancer Center Hauppauge . A dermatologist is a doctor who specializes in skin, hair

New MSK research combined sophisticated genetically engineered mouse models and advanced computational methods to map the earliest cell states leading to pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.

… Thursday, May 11, 2023 Discussions of cancer often stress the genetic mutations that drive disease by altering the normal function of cellular proteins. KRAS , for example, normally acts as an on/off switch for cellular proliferation, but mutations to the gene — common in lung cancer, colorectal cancer